PROTOPIC A STEROID

FDA Approves Protopic (Tacrolimus) Non-Steroidal Ointment For EczemaContact Us | Order Now | Journals |Bookstore | Register a colleague DEERFIELD, IL -- December 11, 2000 -- A new option is on the way for the 15 million Americans who currently suffer from the painfully itchy skin disorder atopic dermatitis, more commonly known as eczema. Today's FDA approval of Protopic marks a milestone for eczema sufferers and treating physicians, says Dr. Amy Paller, Professor of Dermatology and Pediatrics and Chief of Medical School in Chicago, Illinois. As a pediatric dermatologist I see first-hand both the physical and emotional difficulties young eczema sufferers experience. The approval of Protopic finally gives prescribing physicians an effective, non-steroidal option for treating the often painful and frustrating symptoms resulting from eczema. Conventional therapies for eczema have been limited and variable outcomes have been reported. Routine treatment frequently includes the use of steroid creams applied to the skin. Steroids have been associated with side effects including: skin thinning, stretch marks and skin discoloration. Physician and patient satisfaction has been disappointing. Protopic offers physicians another treatment option when conventional treatment is deemed inadvisable because of the potential risks associated with them, or when patients are not adequately responsive to or intolerant of conventional therapies.